论文部分内容阅读
收集５２例呼吸科感染病人静脉输注阿米卡星（ａｍｉｋａｃｉｎ，ＡＭＫ）的临床数据，用荧光偏振兔疫法（ＦＰＩＡ）测定临床病人ＡＭＫ的血清浓度２７５点，按二房室开放模型，用ＮＯＮＭＥＭ程序一步估算出ＡＭＫ的群体药代动力学参数，并定量地分析病人的体重、肌酥清除率、长期用药和病理状况（馒性阻塞性肺病，ＣＯＰＤ）等固定效应对药代动力学参数的影响。经统计分析病人的肌酥清除率和ＣＯＰＤ对ＡＭＫ的药代动力学参数的影响有显著意义，而体重对表现分布容积Ｖｃ的影响无显著意义。由最终回归模型估算出ＡＭＫ的群体药代动力学参数。
The clinical data of 52 AMAM patients receiving intravenous amikacin (amikacin) were collected. The serum AMK concentrations of 275 AMI patients were determined by fluorescence polarization rabbit immunofluorescence staining (FPIA) The program further estimated the pharmacokinetic parameters of AMK population and quantitatively analyzed the effects of fixed effects such as body weight, muscle clearance rate, long-term medication and pathological conditions (diffuse obstructive pulmonary disease, COPD) on pharmacokinetic parameters influences. Statistical analysis of the patient’s muscular crisp clearance and COPD on AMK pharmacokinetic parameters of significance, and body weight on the performance of the distribution of volume Vc of no significant significance. Population pharmacokinetic parameters of AMK were estimated from the final regression model.